Table 5.
Types of claims granted.
| Cancer type | Medicine generic name | PROM | Type of claim granted | Study design |
|---|---|---|---|---|
| ALL | Tisagenlecleucel | PedsQL EQ-5D | HRQoL | Open-label single arm trial |
| Breast Neoplasms | Abemaciclib | BPI EORTC QLQ-C30 EORTC QLQ-BR23 EQ-5D 5L | HRQoL (no difference between groups) | Double-blind RCT |
| Breast Neoplasms | Fulvestrant | EORTC QLQ-C30 EORTC QLQC30 EQ 5D | Symptoms | Double-blind RCT |
| Breast Neoplasms | Pertuzumab | EORTC QLQ-C30 EORTC QLQ-BR23 EQ-5D | Global health status, symptoms, functioning | Double-blind RCT |
| Breast Neoplasms | Ribociclib | EORTC QLQ-C30 EORTC QLQ-BR23 EQ-5D-5L | HRQoL, global health status (no difference between groups) | Double-blind RCT |
| FL | Obinutuzumab | FACT-Lym EQ-5D-3L | Symptoms HRQoL and global health status (no difference between groups) | Open-label RCT |
| HCC | Cabozantinib | EQ-5D-5L | HRQoL | Double-blind RCT |
| HL | Brentuximab Vedotin | EORTC QLQ C30 FACT/GOG-Ntx subscale EQ-5D-3L | HRQoL (no difference between groups) | Open-label RCT |
| Melanoma | Binimetinib | FACT-M EQ-5D-5L EORTC-QLQ-C30 | HRQoL, functioning, symptoms | Open-label RCT |
| Melanoma | Encorafenib | FACT-M EQ-5D-5L EORTC QLQ-C30 | HRQoL, functioning, symptoms | Open-label RCT |
| Melanoma | Nivolumab | EORTC QLQ-C30 EQ-5D WPAI:GH | HRQoL (no difference between groups) | Double-blind RCT |
| NSCLC | Atezolizumab | EORTC QLQ-LC13 | Symptoms | Open-label RCT |
| NSCLC | Atezolizumab | EORTC QLQ-C30 EORTC QLQ-LC13 SILC scale | HRQoL, global helath status (no difference between groups) | Open-label RCT |
| NSCLC | Ceritinib | EORTC QLQ-C30 EORTC QLQ-LC13 LCSS EQ-5D | HRQoL, global helath status, symptoms | Open-label RCT |
| NSCLC | Durvalumab | EORTC QLQ-C30 EORTC QLQ-LC13 WHO PS Scores | HRQoL, functioning, symptoms (no difference between groups) | Double-blind RCT |
| NSCLC | Osimertinib | EORTC QLQ-C30 EORTC QLQ-LC13 | HRQoL,global helath status, functioning, symptoms (no difference between groups) | Double-blind RCT |
| Ovarian Neoplasms | Niraparib | FOSI EQ-5D-5L Neuropathy Questionnaire | HRQoL (no difference between groups) | Double-blind RCT |
| Pancreatic Neoplasms | Lutetium (177Lu) oxodotreotide | EORTC QLQ-30 EORTC G.I.NET21 | HRQoL | Open-label RCT |
| Prostatic Neoplasms | Apalutamide | FACT-P EQ-5D | HRQoL (no difference between groups) | Double-blind RCT |
| Prostatic Neoplasms | Padeliporfin | IPSS IIEF-15 EQ-5D | Symptoms | Open-label RCT |
| T-cell Lymphoma | Brentuximab vedotin | Skindex-29 questionnaire FACT-G EQ-5D-3L | HRQoL (no difference between groups) | Open-label RCT |
| UC | Pembrolizumab | EORTC QLQ-C30 EUROQoL EQ-5D | HRQoL, global health status | Open-label RCT |